



PERMANENTE MEDICINE
Mid-Atlantic Permanente Medical Group

Mid-Atlantic Permanente
Research Institute

Physician Research Scholars Abstracts

McCary A. (Platform Presentation). *Metabolic Dysfunction-Associated Steatotic Liver Disease Diagnosis and Management for the Primary Care Physician. Practice Strategies for Screening, Risk Stratification, and Treatment.* **KP LIFTS Conference**, Las Vegas, NV, April 2025-25, 2025.

McCary A, Sheu Y-S, Chesbrough K, Jonas M. (Poster Presentation). *Improved Liver Fibrosis Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Patients with Hepatitis C Treatment.* **American Association of the Study of Liver Diseases – The Liver Meeting**, San Diego, CA, November 15-19, 2024.

Jacobs JB, Hu H, Kim S, Sheu Y-S, Bishop RC, Chesbrough K, Weinfield NS. (Platform Presentation). *Risk Factors for Development of Type 1 and Prediabetes in Children and Teenagers During the COVID-19 Pandemic.* **American Public Health Association, Meeting and Expo**, Minneapolis, MN, October 27-30, 2024.

Berry N, Sheu Y-S, Chesbrough K, Bishop RC, Vupputuri S. (Poster Presentation). *Rates of Guideline-Directed Medical Therapy Among Patients with Heart Failure with Reduced Ejection Fraction in a Large, Integrated Healthcare System.* **Heart Failure Society of America, Annual Scientific Meeting**, Atlanta, GA, September 27-30, 2024.

Jacobs JB, Kim S, Sheu Y-S, Chesbrough K, Bishop RC, Weinfield NS. (Platform Presentation). *Trends and Incidence of Type 1, Type Diabetes, and Prediabetes in Children and Teens through the COVID-19 Pandemic: An Interrupted Time Series Analysis.* **Pediatric Academic Societies, Annual Meeting**, Toronto, Canada, May 2-6, 2024.

Wenk KS. (Poster Presentation). *Methotrexate Test Dose Use and Frequency of Laboratory Abnormalities in Patients Initiating Treatment.* **American Academy of Dermatology, Annual Meeting**, San Diego, CA, March 9, 2024.

Wenk KS. (Poster Presentation). *Frequency of Hepatic Laboratory Abnormalities in Patients with Non-alcoholic Fatty Liver Disease During Treatment with Oral Terbinafine for Onychomycosis.* **American Academy of Dermatology, Annual Meeting**, San Diego, CA, March 9, 2024.

Wenk KS. (Poster Presentation). *Frequency of Laboratory Abnormalities during Terbinafine Therapy for Onychomycosis.* **Atlantic Dermatology Conference**, Philadelphia, PA, May 12 – 13, 2022. **Category Winner: Dermatology Quality Improvement and Quality Assessment Projects.**

Sznajder K. (Poster Presentation). *Contraceptive Use by Females with Chronic Medical Conditions in a Large Integrated Healthcare System.* **Society of Family Planning, Annual Meeting**, Baltimore, MD, December 3 -5, 2022.

Burrell TD. (Poster Presentation). *A Digital Intervention for Adolescents with Mental Illness in a Time of Need (The DIAMoNd Study).* **American Public Health Association, Annual Meeting**, Boston, MA. November 6 – 9, 2022.

Burrell TD. (Poster Presentation). *Predictors of Adolescent Outpatient Mental Health Service Utilization during the COVID-19 Pandemic.* **American Academy of Pediatrics, National Conference and Exhibition,** Anaheim, CA, October 7 – 11, 2022.

Sznajder K. (Poster Presentation). *Characteristics and Outcomes Associated with COVID-19 Infection in Pregnancy.* **American College of Obstetrics and Gynecology, Annual Clinical and Scientific Meeting,** San Diego, CA, May 6 – 8, 2022.

Burrell TD. (Poster Presentation). *Adolescent Mental Healthcare Utilization during the COVID-19 Pandemic.* **Society for Adolescent Health and Medicine, Annual Meeting,** San Diego, CA, March 9 – 12, 2022.